Introduction to the new anti-cancer drug Iressa, gefitinib and Iressa 13621079267 Iressa price

Beijing, China - AstraZeneca, the world's leading pharmaceutical company, announced that the new anti-cancer drug Iressa (gefitinib) has been approved by the State Food and Drug Administration to be officially launched in China. Treatment of locally advanced or metastatic non-small cell lung cancer previously treated with chemotherapy. Iressa is a new breakthrough in the field of cancer treatment. It is the world's first epidermal growth factor receptor tyrosine kinase inhibitor, and its mechanism of action is different from that of cytotoxic drugs. The launch of Iressa in China will change traditional treatment methods and bring new hope to Chinese patients with locally advanced or metastatic non-small cell lung cancer who have failed previous chemotherapy and their families. But the horribly high price has plunged patients into despair again!
A year later, India's Iressa was launched in China and was produced by India's second largest pharmaceutical company.